title: A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
abstract: A "Soft" corticosteroid, loteprednol etabonate I, designed based on the "inactive metabolite" concept can be used as a safe ophthalmic anti-inflammatory drug. By design, the metabolism of I follows a predicted biotransformation pathway, thus unwanted systemic side effects are avoided. Local side effects are also reduced. Accordingly, in a cross-over study I did not elevate the intraocular pressure (IOP) in rabbits, as opposed to dexamethasone.
authors.affiliation: Center for Drug Discovery, J.Hillis Miller Health Center, College of Pharmacy, University of Florida, Gainesville 32610.
authors.forename: N
authors.initials: N
authors.lastname: Bodor
authors.forename: N
authors.initials: N
authors.lastname: Bodor
authors.forename: W M
authors.initials: WM
authors.lastname: Wu
mesh_terms: D000287:Administration, Topical; D000730:Androstadienes / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology*; D007429:Intraocular Pressure / Q000187:drug effects*; D000069559:Loteprednol Etabonate; D011817:Rabbits; D014065:Tonometry, Ocular
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D003907:Dexamethasone; D000069559:Loteprednol Etabonate